Abstract Currently, there is no disease-modifying treatment available for Alzheimers and Parkinsons disease (AD and PD) and that includes the highly controversial approval of the A-targeting antibody aducanumab for the treatment of AD
Herman, J
The timing varies based on your kidney function, overall health, and specific institutional protocols
Warning signs include decreased urine output, dark concentrated urine, persistent nausea or vomiting lasting more than 24 hours, dizziness suggesting dehydration, unexplained fatigue, and leg swelling
It can influence gut activity and may also help slow the breakdown of GLP-1 in the body
however, it may restore the inner surface area of the bladder, which safeguards the bladder wall surface from substances in urine that could irritate it